Clinical trial · Interventional
Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy
Comparison of Volatile and IV Anesthesia on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aim to observe and compare the change of alarmins such as high mobility group nucleosome-binding protein-1 (HMGN1), high mobility group proteins b1 (HMGb1), Interleukin (IL)-33 and their soluble receptors including soluble toll like receptor 4 (sTLR4) and soluble ST2 (sST2) during pulmonary lobectomy for cancer patients receiving volatile anesthesia or intravenous anesthesia under one-lung ventilation (OLV). By which, this study will preliminarily evaluate the correlation of alarmins and prognosis as well as the effect of inhalational and intravenous anesthesia on the prognosis of surgical patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Propofol | Drug | — | UNRESOLVED |
| Sevoflurane | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- volatile anesthesia
- description
- Use 2-3% sevoflurane to maintain the anesthesia during OLV surgery with bispectral index (BIS) 40-60.
- interventionNames
- Drug: Sevoflurane
- type
- ACTIVE_COMPARATOR
- label
- intravenous anesthesia
- description
- Anesthesia was maintained by a continuous infusion of propofol （4-6mg/kg/h）with BIS 40-60.
- interventionNames
- Drug: Propofol
Primary outcomes (5)
- measure
- Change of level of HMGN1
- timeFrame
- 10 min before OLV, 10 min after OLV, 1 day and 2 day after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * American society of Anesthesiology (ASA) status I-II * pathological diagnosis of lung cancer before surgery * receive pulmonary lobectomy * with normal lung function * without heart failure (NYHA\>2), obstructive or restrictive lung disease * no history of other malignancy tumor * body mass index (Body mass, index, BMI) \< 35kg/m2 * no severe coagulopathy * no severe systemic or pulmonary infection * did not participate in other clinical trials Exclusion Criteria: * persistent smoking history * immunosuppressive drug use 6 weeks before operation * receive total pneumonectomy * failure to complete treatment or follow-up * severe adverse drug reactions * severe postoperative complications
References
Publications (0)
Data not yet available